Possibilities in this area include buprenorphine or high-dose DCS after ketamine response [265], low-dose naltrexone for inflammatory-related depression [266], or corticotropin releasing factor receptor antagonists for stress-sensitive forms of depression [267]. The gene discussed is CRHR1; the disease is depressive disorder.